Aktuelt
Aktuelt
Her kan du lese mer om hva som skjer i vår virksomhet.
For deg som jobber i media og ønsker å få tilgang til våre pressemeldinger, vennligst klikk på lenken nedenfor.
Denne siden er ment for deg som jobber i media. På denne siden finner du Italfarmacos pressemeldinger, beregnet for media, presse og journalister.
Ved å fortsette bekrefter du at du jobber i media. Ønsker du å gå videre til pressemeldingene?
2024 - September 6
7. september markeres Verdensdagen for Duchennes muskeldystrofi (WDAD), en sykdom vi som selskap er spesielt involvert i.
Corporate News
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
function openWindowReload(link)
Press review
2024 – March 21
Business Wire
Italfarmaco receives FDA approval for givinostat in Duchenne muscular dystrophy (DMD)
March 21, 2024 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
function openWindowReload(link)
2024 – March 19
Business Wire
Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)
March 19, 2024 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
function openWindowReload(link)
2023 – September 05
Business Wire
Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy
September 05, 2023 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
function openWindowReload(link)
2023 – June 29
Business Wire
Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review
June 29, 2023 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
function openWindowReload(link)
2022 – June 25
Business Wire
Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy
June 25, 2022 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
function openWindowReload(link)
Corporate Press
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
function openWindowReload(link)